ADMP Research and Charts

ADMP - Adamis Pharmaceuticals Corp (Healthcare: Drug Manufacturers - Specialty & Generic)

Projected Earnings Date: 2024-02-16 (Delayed quote data )

Last	Change ⇓ 0.00 (%)	Volume 0
	Open	High	Low

8EMA (Daily) 0.00	40EMA (Daily)	50EMA (Daily)	STO (Daily)	MACD Hist (Daily)
8EMA (Weekly) 1.204	40EMA (Weekly) 7.35	50EMA (Weekly) 9.83	STO (Weekly) 0.834	MACD Hist (Weekly) 0.735


Company Profile
Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-1000) intended for the treatment of asthma.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.